After a period of clinical recalibration, the ALS and FTD field is regaining momentum, driven by a deeper biological understanding, more refined translational strategies, and continued industry commitment.
Recent moves across the sector reflect this renewed focus. From Eli Lilly’s Alchemab-supported ALS expansion to genetically informed collaborations from BMS and insitro, and Clene Nanomedicine’s progress toward regulatory approval, the message is clear: there’s a shared determination to advance truly disease-modifying therapies.
The pipeline reflects this progress. Today, over 475 therapies are in development, with 157 clinical trials either active or enrolling, and more than 350 companies involved in ALS research.
With the global ALS market expected to grow from USD 667.3 million in 2023 to nearly USD 1 billion by 2030, the field is applying hard-earned lessons to build more predictive, mechanism-based programs. This includes advancing our understanding of TDP-43 gain- and loss-of-function, cryptic exon regulation, neuroinflammation, and leveraging human-relevant iPSC and 3D disease models.
To drive this next phase forward, the 5th ALS Drug Development Summit will unite over 100 senior experts spanning discovery, translational research, clinical development, regulatory science, investment, and patient advocacy.
Featuring 30+ speakers from organizations including AbbVie, AskBio, Biogen, Eli Lilly, Novartis, QurAlis, Prilenia Therapeutics, Mitsubishi Tanabe Pharma, uniQure, ROME Therapeutics, Everything ALS, and Sanofi, the summit is one of the best meeting points for the ALS and FTD community to align on the path ahead.
This year’s key themes include:
- Tackling core ALS and FTD disease biology
- Addressing heterogeneity through smarter patient stratification
- Translational strategies that improve clinical predictability
- Progress in TDP-43 and cryptic exon biology
- Targeting neuroinflammatory pathways with novel approaches
- Integrating iPSC and 3D models for more human-relevant insights
About Hanson Wade Group - 5th Annual ALS Drug Development Summit
Bolstering a Resurgence in Novel Approaches to Target Underlying Pathology, Address Disease Heterogeneity & Restore Hope in a More Transformative Wave of ALS & FTD Therapies
Uniting ALS Biotech, Pharma & Academia to Accelerate the Next Generation of ALS & FTD Therapeutics
Strategic moves across the sector - from Eli Lilly's Alchemab-backed ALS expansion to BMS and insistro's genetically driven collaboration and Clene Nanomedicine's regulatory-stage program - underscore the ALS community’s continued commitment to advancing impactful therapies, even in the face of clinical setbacks.
With over 475 therapies in development, and 157 active or enrolling trials, and more than 350 companies actively working in ALS, and a global ALS market projected to grow from USD 667.3 M in 2023 to USD 987.6 M by 2030, confidence is returning. Learnings, fuelled by stronger mechanistic hypotheses, and more resilient translational strategies, spanning TDP 43 loss and gain of function biology, cryptic exon regulation, neuroinflammatory pathways, and human relevant iPSC and 3D models, the ALS community is leveraging these lessons to build smarter, more predictive programs.
Uniting 100+ senior experts across discovery, translational research, clinical development, regulatory science, investment, and patient advocacy, 30+ speakers from AbbVie, AskBio, Biogen, Eli Lilly, Novartis, QurAlis, Prilenia Therapeutics, Mitsubishi Tanabe Pharma, uniQure, ROME Therapeutics, Everything ALS, Sanofi, and more, this is the definitive forum restoring hope across the ALS & FTD community.
Download the Event Guide
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.